Navigation Links
Interim Analysis of Data from e-HEALING Registry of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Date:11/7/2008

Sigmund Silber to Highlight 12-Month Patient Subset Results in Oral

Presentation

HONG KONG, Nov. 7 /PRNewswire/ -- An interim analysis of 12-month patient subset data from e-HEALING, a global post-marketing surveillance registry of OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans.

Sigmund Silber, M.D., F.A.C.C., F.E.S.C., a professor of medicine with the Cardiology Practice and Hospital, Munich, will present the data at 9:30 a.m. CST on Nov. 12 in Auditorium C at the Ernest N. Morial Convention Center. Silber and Robbert de Winter, M.D., Ph.D., F.E.S.C., a professor of medicine with the Academic Medical Center, Amsterdam, are the co-principal investigators of e-HEALING.

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients treated with the Genous Bio-engineered R stent. The study protocol recommends that patients receive one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary endpoint of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Sapphire(TM) NC, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
2. Misonix Announces Interim Distribution Agreement for Italy
3. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. Arpida Reports Interim Results for Six Months to 30 June 2008
6. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
7. LPBP Inc. - Re-filing certification of interim filings
8. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
9. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
Breaking Biology Technology:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
Breaking Biology News(10 mins):